JUPITER NEUROSCIENCES, INC.
JUNSNasdaq
$0.17
↓ -0.9%Jul 17 close · end-of-day
Price
1Y↓ -92.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$6.1M
Enterprise Value
$6.1M
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$9.2M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
329.7%
ROIC
—
Debt / Equity
—
Net Cash
—
Return 1Y
-90.0%
Company profile
Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company located in Jupiter, Florida. The Company incorporated in Delaware in January 2016. The Company has developed a unique resveratrol platform product primarily targeting treatment of neuro-inflammation. The product candidate, called JOTROL™, has many potential indications of use for rare diseases, which of we primarily are targeting Mucopolysaccharidoses Type 1, Friedreich’s Ataxia, and MELAS and with ALS in an earlier development stage. We are currently incorporated and in good standing in the State of Delaware. Our principal executive offices are located at 1001 North US Hwy 1, Suite 504, Jupiter, Florida.
- CEO
- Christer Rosén
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 4
- Headquarters
- Florida
- Website
- jupiterneurosciences.com
Management & directors
- Rosen ChristerCEO and Chairman
- Silva Alison D.Pres + Chief Business Officer
Roles derived from SEC Form 4 filings.
Earnings
JUNS Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$18,652.00—
Diluted EPS-$0.06↑ +20.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | $0.00 | $21,796.00 |
| Gross profit | — | — | $17,565.00 |
| Operating income | -$3.9M | -$3.1M | -$8.9M |
| Net income | -$4.8M | -$2.4M | -$8.6M |
| Diluted EPS | -$0.18 | -$0.08 | -$0.25 |
| Operating cash flow | -$480,953.00 | -$3.9M | -$5.4M |
| Free cash flow | — | — | — |
| Gross margin | — | — | 80.6% |
| Operating margin | — | — | -40873.2% |
| Net margin | — | — | -39662.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0.00 | — | — | — | $18,652.00 |
| Gross profit | — | — | — | — | — | — | — | $14,290.00 |
| Operating income | -$557,077.00 | -$493,547.00 | -$1.5M | -$1.5M | -$2.3M | -$2.3M | -$2.8M | -$2.0M |
| Net income | $313,123.00 | -$591,021.00 | -$1.5M | -$1.5M | -$2.3M | -$2.3M | -$2.6M | -$2.1M |
| Diluted EPS | $0.01 | -$0.02 | -$0.05 | -$0.05 | -$0.07 | -$0.07 | -$0.06 | -$0.06 |
| Operating cash flow | -$107,462.00 | -$42,598.00 | -$3.7M | -$1.1M | -$828,222.00 | -$1.2M | -$2.4M | -$1.4M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | 76.6% |
| Operating margin | — | — | — | — | — | — | — | -10524.3% |
| Net margin | — | — | — | — | — | — | — | -11054.9% |
Company news
May 20, 2026
- 61d agoJupiter Neurosciences Announces Pricing of $2.0 Million Registered Direct Offeringfinance.yahoo.com
- 61d agoPharmAla Biotech Signs Term Sheet for $100 Million U.S. Licensing Deal for ALA-002 MDMA Therapy (MDXXF)investorshub.advfn.com
- 61d agoPharmAla Biotech Signs Term Sheet to License Exclusive U.S. Rights to ALA-002, Its Next-Generation MDMA Therapeutic, to Jupiter Neurosciences, Inc. (NASDAQ: JUNS) in a Transaction Valued at Over $100 Millionfinance.yahoo.com
- 61d agoJupiter Neurosciences Secures $100M Term Sheet for Exclusive U.S. Rights to ALA-002, a Next-Generation MDMA Therapeutic from PharmAla Biotechfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-07-01 | ROSEN CHRISTER· CEO and Chairman | Buy | 3,100 | $1.02 | $3,162.00 | filing |
| 2025-07-01 | ROSEN CHRISTER· CEO and Chairman | Buy | 500 | $1.01 | $505.00 | filing |
| 2025-07-01 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.03 | $258.50 | filing |
| 2025-07-01 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.03 | $257.18 | filing |
| 2025-07-01 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.03 | $256.58 | filing |
| 2025-06-30 | ROSEN CHRISTER· CEO and Chairman | Buy | 2,000 | $1.01 | $2,020.00 | filing |
| 2025-06-30 | ROSEN CHRISTER· CEO and Chairman | Buy | 1,500 | $1.04 | $1,560.00 | filing |
| 2025-06-30 | ROSEN CHRISTER· CEO and Chairman | Buy | 1,450 | $1.02 | $1,479.00 | filing |
| 2025-06-30 | ROSEN CHRISTER· CEO and Chairman | Buy | 1,000 | $1.05 | $1,050.00 | filing |
| 2025-06-30 | ROSEN CHRISTER· CEO and Chairman | Buy | 1,000 | $0.98 | $980.00 | filing |
| 2025-06-30 | ROSEN CHRISTER· CEO and Chairman | Buy | 700 | $1.03 | $721.00 | filing |
| 2025-06-30 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.04 | $259.20 | filing |
| 2025-06-30 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.03 | $257.50 | filing |
| 2025-06-30 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.02 | $255.00 | filing |
| 2025-06-30 | Silva Alison D.· Pres + Chief Business Officer | Buy | 100 | $1.05 | $104.96 | filing |
| 2025-06-30 | Silva Alison D.· Pres + Chief Business Officer | Buy | 100 | $1.02 | $101.68 | filing |
| 2025-06-27 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.05 | $262.50 | filing |
| 2025-06-27 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.04 | $260.88 | filing |
| 2025-06-27 | Silva Alison D.· Pres + Chief Business Officer | Buy | 250 | $1.00 | $250.00 | filing |
| 2025-06-27 | ROSEN CHRISTER· CEO and Chairman | Buy | 166 | $1.06 | $175.96 | filing |
| 2025-06-27 | Silva Alison D.· Pres + Chief Business Officer | Buy | 100 | $1.04 | $103.50 | filing |
Latest 21 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.